LOGIN  |  REGISTER
Recursion

Harrow Announces Participation in Upcoming Investor Conferences

November 15, 2024 | Last Trade: US$40.32 0.62 1.56

NASHVILLE, Tenn. / Nov 15, 2024 / Business Wire / Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in the following three investor conferences:

Craig-Hallum 15th Annual Alpha Select Conference (Sheraton New York Times Square Hotel)
November 19, 2024
1x1 Meetings Only

BTIG 4th Annual Ophthalmology Day (Virtual)
December 2, 2024
1x1 Virtual Meetings Only

Piper Sandler 36th Annual Healthcare Conference (The Lotte New York Palace)
December 3-5, 2024
Company will host a Fireside Chat at 8:00 a.m. ET on December 4, 2024

The Company will conduct one-on-one meetings at each conference. Investors interested in meeting with management during conferences should contact their representative at each firm to request a meeting. Only the Piper Sandler conference will include an audio webcast, which will be available on the Company’s website.

About Harrow

Harrow, Inc. (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the North American market. Harrow helps eyecare professionals preserve the gift of sight by making its portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of patients each year. For more information about Harrow, please visit harrow.com.

Chimerix

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB